136sek
4,6 %
Date:2024-05-03Time:11:25:44Latest report:Q4-2023List:First NorthTicker:SCOL
Market Cap:55 msekEnterprise Value:16 msekNet Sales:- mdkkEarnings:-39,2 mdkkEmployees:0ISIN:DK0061031895

Ratios

10-year key figure history for Scandion Oncology turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Scandion Oncology with index and moving average MA50 and MA200.

Stockprice:1,36
MA50:2,14
MA200:2,16
Price/MA200:-37,3 %
RSI (14):33,1
Price/MA50:-36,8 %

Description

Scandion Oncology A/S is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Biotechnology